Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.
Upasani V, Townsend K, Wu MY, Carr EJ, Hobbs A, Dowgier G, Ragno M, Herman LS, Sharma S, Shah D, Lee SFK, Chauhan N, Glanville JM, Neave L, Hanson S, Ravichandran S, Tynan A, O'Sullivan M, Moreira F, Workman S, Symes A, Burns SO, Tadros S, Hart JCL, Beale RCL, Gandhi S, Wall EC, McCoy L, Lowe DM. Upasani V, et al. Among authors: ravichandran s. Clin Infect Dis. 2023 Oct 5;77(7):950-960. doi: 10.1093/cid/ciad368. Clin Infect Dis. 2023. PMID: 37338118 Free PMC article.
A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis.
Ravichandran S, Hall A, Jenner M, Garg M, Kishore B, Lachmann H, Gillmore J, Pitchford A, Oughton JB, Mahmood S, Sachchithantham S, Hawkins P, Brown S, Wechalekar A. Ravichandran S, et al. Amyloid. 2023 Sep;30(3):290-296. doi: 10.1080/13506129.2023.2169124. Epub 2023 May 22. Amyloid. 2023. PMID: 37216268 Clinical Trial.
Refining prognostication in systemic AL amyloidosis: limited value of dFLC.
Khwaja J, Ravichandran S, Bomsztyk J, Cohen O, Foard D, Martinez-Naharro A, Venneri L, Fontana M, Whelan C, Hawkins PN, Gillmore JD, Lachmann HJ, Mahmood S, Wechalekar A. Khwaja J, et al. Among authors: ravichandran s. Amyloid. 2024 Dec;31(4):353-355. doi: 10.1080/13506129.2024.2406845. Epub 2024 Sep 23. Amyloid. 2024. PMID: 39311543 No abstract available.
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Cohen OC, Brodermann MH, Blakeney IJ, Mahmood S, Sachchithanantham S, Ravichandran S, Law S, Lachmann HJ, Whelan CJ, Popat R, Rabin N, Yong K, Kyriakou C, Shah R, Cheesman S, Worthington S, Hawkins P, Gillmore JD, Wechalekar AD. Cohen OC, et al. Among authors: ravichandran s. Amyloid. 2020 Sep;27(3):200-205. doi: 10.1080/13506129.2020.1765768. Epub 2020 May 15. Amyloid. 2020. PMID: 32408823 Clinical Trial.
Complete responses in AL amyloidosis are unequal: the impact of free light chain mass spectrometry in AL amyloidosis.
Bomsztyk J, Ravichandran S, Giles HV, Wright N, Berlanga O, Khwaja J, Mahmood S, Wisniowski B, Cohen O, Foard D, Gilbertson J, Rauf MU, Starr N, Martinez-Naharro A, Venneri L, Whelan C, Fontana M, Hawkins PN, Gillmore JD, Lachmann H, Harding S, Pratt G, Wechalekar AD. Bomsztyk J, et al. Among authors: ravichandran s. Blood. 2024 Mar 28;143(13):1259-1268. doi: 10.1182/blood.2023022399. Blood. 2024. PMID: 38194690
Haematologic responses and survival do not significantly decrease with subsequent lines of therapy in systemic immunoglobulin light chain amyloidosis: results from an analysis of real-world longitudinal data.
Ravichandran S, Cohen OC, Law S, Sachchithanantham S, Mahmood S, Foard D, Fontana M, Martinez-Naharro A, Whelan C, Gillmore JD, Lachmann HJ, Hawkins PN, Wechalekar AD. Ravichandran S, et al. Br J Haematol. 2021 Aug;194(3):587-597. doi: 10.1111/bjh.17636. Epub 2021 Jun 29. Br J Haematol. 2021. PMID: 34189728
Redefining Cardiac Involvement and Targets of Treatment in Systemic Immunoglobulin AL Amyloidosis.
Porcari A, Masi A, Martinez-Naharro A, Razvi Y, Patel R, Ioannou A, Rauf MU, Sinigiani G, Wisniowski B, Filisetti S, Currie-Cathey J, O'Beara S, Kotecha T, Knight D, Moon JC, Sinagra G, Virsinskaite R, Gilbertson J, Venneri L, Petrie A, Lachmann H, Whelan C, Kellman P, Ravichandran S, Cohen O, Mahmood S, Manisty C, Hawkins PN, Gillmore JD, Wechalekar AD, Fontana M. Porcari A, et al. Among authors: ravichandran s. JAMA Cardiol. 2024 Nov 1;9(11):982-989. doi: 10.1001/jamacardio.2024.2555. JAMA Cardiol. 2024. PMID: 39167388 Free PMC article.
Prognostic importance of the 6 min walk test in light chain (AL) amyloidosis.
Cohen OC, Sathyanath A, Petrie A, Ravichandran S, Law S, Manwani R, Foard D, Sachchithanantham S, Mahmood S, Martinez-Naharro A, Fontana M, Whelan CJ, Hawkins PN, Lachmann HJ, Gillmore JD, Wechalekar AD. Cohen OC, et al. Among authors: ravichandran s. Heart. 2022 Sep 26;108(20):1616-1622. doi: 10.1136/heartjnl-2021-320703. Heart. 2022. PMID: 35764371
Response rates to second-line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib-based regime.
Bomsztyk J, Ravichandran S, Khwaja J, Cohen O, Rauf MU, Foard D, Martinez-Naharro A, Venneri L, Whelan C, Fontana M, Hawkins PN, Gillmore J, Lachmann H, Mahmood S, Wechalekar AD. Bomsztyk J, et al. Among authors: ravichandran s. Br J Haematol. 2024 Jul;205(1):138-145. doi: 10.1111/bjh.19529. Epub 2024 Jun 5. Br J Haematol. 2024. PMID: 38840512
408 results